Camptocormia in Parkinson's Disease

Table 1

Demographic and clinical details of Parkinson’s disease patients with and without camptocormia, and controls.

	Controls	PD	PD with camptocormia	PD without camptocormia
Number	27	153	27	27
mean age ($\pm$sd) (years)	$67.4\pm 8.9$	$68.5\pm 10.7$	$69.2\pm 10.1$	$67.9\pm 7.9$
sex (m)		70	11	11
mean duration of disease (years)		$5.9\pm 2.4$	$6.0\pm 2.7$	$6.1\pm 3.9$
drugs (levodopa equivalent doses (mg), (mean $\pm$ sd))		$432\pm 212$	$440\pm 221$	$427\pm 203$
Hohen-Yahr staging (mean $\pm$ sd)		$3.0\pm 0.7$	$3.1\pm 0.5$	$3.1\pm 1.6$
UPDRS (Part III) (mean $\pm \mathrm{\hspace{0.17em}\hspace{0.17em}}$sd)		$34.0\pm 16.0$	$30.4\pm 5.3$	$32.5\pm 5.1$
MMSE (mean)	28.6	27.8	$27.6$	27.9
FAB (mean $\pm$ sd)	$16.2\pm 0.8$		$15.1\pm 1.5$	$13.7\pm 1.6$ ^#,*
PDQ-8 (mean $\pm$ sd)			$16.0\pm 6.1$	$20.4\pm 4.6$ ^#,*
HADS-depression (mean $\pm$ sd)without depression $\leqq$8	$4.6\pm 3.4$		$8.6\pm 5.4$ ^#	$8.3\pm 5.1$ ^#
HADS-anxiety (mean $\pm$ sd) without anxiety $\leqq$11	$5.9\pm 4.3$		$8.0\pm 4.8$	$8.8\pm 6.4$
FSQ (mean $\pm$ sd)	$2.4\pm 0.8$		$4.1\pm 1.3$^#	$4.8\pm 1.0$ ^#,*
VAS-F (mean $\pm$ sd)	$30.8\pm 10.2$		$48.0\pm 18.5\hspace{0.17em}$^#	$62.1\pm 17.8$ ^#,*
PDSS (mean $\pm$ sd)	$120.0\pm 14.8$		$70.4\pm 26.0$ ^#	$69.5\pm 17.3$ ^#
NMSS (mean $\pm$ sd)			$46.5\pm 21.1$	$55.7\pm 15.5$ *

^#comparing with controls.
*comparing with PD without camptocormia.